Transforming cancer prevention through precision medicine and immune-oncology

Cancer Prevention Research

Volumn 9, Issue 1, 2016, Pages 2-10

  Kensler, Thomas W ^a   Spira, Avrum ^b   Garber, Judy E ^c   Szabo, Eva ^d   Lee, J Jack ^e   Dong, Zigang ^f   Dannenberg, Andrew J ^g   Hait, William N ^h   Blackburn, Elizabeth ⁱ   Davidson, Nancy E ^j   Foti, Margaret ^k   Lippman, Scott M ^l  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b BOSTON UNIVERSITY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h JANSSEN RESEARCH AND DEVELOPMENT   (United States)

ⁱ SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^j UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^k American Association for Cancer Research   (United States)

^l UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; VIRUS VACCINE; CANCER VACCINE; IMMUNOSUPPRESSIVE AGENT; TUMOR MARKER;

ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER PATIENT; CANCER PREVENTION; CANCER SCREENING; CHEMOPROPHYLAXIS; DRUG EFFICACY; EPIDEMIC; HEMATOPOIESIS; HUMAN; LIVER CANCER; LUNG CANCER; NEXT GENERATION SEQUENCING; NONHUMAN; OROPHARYNX CANCER; OVARY CANCER; PANCREAS CANCER; PAPILLOMAVIRUS INFECTION; PERSONALIZED MEDICINE; PRECANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR MICROENVIRONMENT; ANIMAL; BIOPSY; DISEASE COURSE; DNA SEQUENCE; FEMALE; GENETIC PREDISPOSITION; GERMLINE MUTATION; IMMUNE SYSTEM; IMMUNOLOGY; MALE; METABOLISM; MOUSE; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; BIOMARKERS, TUMOR; BIOPSY; CANCER VACCINES; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; NEOPLASMS; PRECANCEROUS CONDITIONS; PRECISION MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEQUENCE ANALYSIS, DNA; TUMOR MICROENVIRONMENT;

EID: 84955306452     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0406     Document Type: Article

References (101)

1. Tomasetti C, Vogelstein B. Cancer risk: role of environment. Science 2015;6223:729-31.
2. Wu S, Powers S, Zhu W, Hannun YA. Substantial contribution of extrinsic risk factors to cancer development. Nature 2015; Dec 16. doi: 10.1038/nature16166. [Epub ahead of print].
3. Potter JD. The failure of cancer chemoprevention. Carcinogenesis 2014;5:974-82.
4. Meyskens FL Jr, Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, et al. Cancer prevention: obstacles, challenges and the road ahead. J Natl Cancer Inst 2015;108:djv309.
5. Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: Current status and future directions. CA Cancer J Clin 2015;5:345-83.
6. Bloom DE, Cafiero ET, Jane-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, et al. The global economic burden of non-communicable diseases. Geneva (Switzerland): World Economic Forum; 2011.
7. Blackburn EM. Cancer Interception. Cancer Prev Res 2011;6:787-92.
8. Herbst RS, Heymach JV, Lippman SM. Lung Cancer. N Engl J Med 2008; 13:1367-80.
9. Nakachi I, Rice JL, Coldren CD, EdwardsMG, Stearman RS, Glidewell SC, et al. Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions. Cancer Prev Res 2014;2:255-65.
10. Ooi AT, Gower AC, Zhang KX, Vick JL, Hong L, Nagao B, et al. Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev Res 2014;5:487-95.
11. Izumchenko E, Chang X, Brait M, Fertig E, Kagohara LT, Bedi A, et al. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat Commun 2015;6:8258.
12. Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005;17:7568-72.
13. Kadara H, Shen L, Fujimoto J, Saintigny P, Chow CW, Lang W, et al. Characterizing the molecular spatial and temporal field of injury in earlystage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res 2013;6:8-17.
14. Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010;26:26ra25.
15. Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The Genetic evolution of melanoma from precursor lesions. N Engl J Med 2015;20:1926-36.
16. Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet 2015;9: 996-1002.
17. Rettig EM, Chung CH, Bishop JA, Howard JD, Sharma R, Li RJ, et al. Cleaved NOTCH1 expression pattern in head and neck squamous cell carcinoma is associated with NOTCH1 mutation, HPV status, and highrisk features. Cancer Prev Res 2015;4:287-95.
18. Sakr RA, Schizas M, Carniello JV, Ng CK, Piscuoglio S, Giri D, et al. Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: repertoire of somatic genetic alterations and clonal relationships. Mol Oncol 2015; Nov 14. pii:S1574-7891(15) 00200-8. doi: 10.1016/j.molonc.2015.11.001. [Epub ahead of print].
19. Permuth-Wey J, Chen DT, Fulp WJ, Yoder SJ, Zhang Y, Georgeades C, et al. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas. Cancer Prev Res 2015;9: 826-34.
20. Stachler MD, Taylor-Weiner A, Peng S, McKenna A, Agoston AT, Odze RD, et al. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet 2015;9:1047-55.
21. Campbell J, Mazzilli S, Reid M, Platero S, Beane J, Spira A. The case for a PreCancer Genome Atlas (PCGA). Cancer Prev Res 2016;2 (in press).
22. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014;26:2488-98.
23. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015;1:9-16.
24. Kwok B, Hall JM, Witte JS, Xu Y, Reddy P, Lin K, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood 2015;21:2355-61.
25. Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med 2015;1:35-47.
26. Wong TN, Ramsingh G, Young AL. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 2015;7540:552-5.
27. Cargo CA, Rowbotham N, Evans PA, Barrans SL, Bowen DT, Crouch S, et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood 2015;21:2362-5.
28. Dhodapkar MV, Sexton R Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood 2015;22:2475-8.
29. Chen AC, Martin AJ, Choy B, Fernandez-Peñas P, Dalziell RA, McKenzie CA, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med 2015;17:1618-26.
30. Baron JA, Barry EL, Mott LA, Rees JR, Sandler RS, Snover DC, et al. A trial of calcium and vitamin D for the prevention of colorectal adenomas. N Engl J Med 2015;16:1519-30.
31. Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet 2001;9260:925-9.
32. William WN Jr,Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, et al. Erlotinib and the risk of oral cancer: the erlotinib prevention of oral cancer (EPOC) randomized clinical trial. JAMA Oncol 2015; 5:1-8.
33. Bauman JE, Grandis J. Oral cancer chemoprevention-the end of EPOC, the beginning of an epoch of molecular selection. JAMA Oncol. 2015; 10.1001/jamaoncol. 2015.4637:1-2.
34. Chubak J, Kamineni A, Buist DSM, Anderson ML, Whitlock EP. Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality; 2015
35. Bezawada N, Song M, Wu K, Mehta RS, Milne GL, Ogino S, et al. Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs. Cancer Prev Res 2014;7:758-65.
36. Fink SP, Yamauchi M, Nishihara R, Jung S, Kuchiba A, Wu K, et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med 2014; 6:233re2.
37. Nan H, Hutter CM, Lin Y, Jacobs EJ, Ulrich CM, White E, et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA 2015;313:1133-42.
38. Guda K, Fink SP, Milne GL, Molyneaux N, Ravi L, Lewis SM, et al. Inactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance. Cancer Prev Res 2014;8:805-12.
39. Holla VR, Backlund MG, Yang P, Newman RA, DuBois RN. Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res 2008;2:93-9.
40. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;17:1596-606.
41. Zhao LN, Li JY, Yu T, Chen GC, Yuan YH, Chen QK. 5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis. PLoS One 2014;4:e94208.
42. Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hofflich H, et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther 2016;1: 83-95.
43. Farrar CT, DePeralta DK, Day H, Rietz TA, Wei L, Lauwers GY, et al. 3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model. J Hepatol 2015; 3:689-96.
44. Gorden DL, Myers DS, Ivanova PT, Fahy E, Maurya MR, Gupta S, et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J Lipid Res 2015;3:722-36.
45. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;9972: 956-65.
46. Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun 2015;6:7686.
47. Barrett CL, DeBoever C, Jepsen K, Saenz CC, Carson DA, Frazer KA. Systematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapy. Proc Natl Acad Sci U S A 2015;23:E3050-7.
48. Imperiale TF, Ransohoff DF, Itzkowitz SH. Multitarget stool DNAtesting for colorectal-cancer screening. N Engl J Med 2014;2:187-8.
49. Silvestri GA, Vachani A, Whitney D, Elashoff M, Porta Smith K, Ferguson JS, et al. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med 2015;3:243-51.
50. Rahman N. Realizing the promise of cancer predisposition genes. Nature 2014;7483:302-8.
51. Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 2015;24:2336-46.
52. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Eng J Med 2005;18:1851-60.
53. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015;2:223-62.
54. Burn J, Gerdes AM,Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011;9809:2081-7.
55. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;26:2509-20.
56. Samadder NJ, Neklason D, Kanth P, Byrne KR, Samowitz W, Jasperson K, et al. Effect of COX and EGFR inhibition on duodenal neoplasia in familial adenomatous polyposis: a randomized placebo-controlled trial. Gastroenterology 2015;4:S93-4.
57. Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res 2011;5:655-65.
58. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;3:244-50.
59. Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2013;25:3091-9.
60. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet2013;9:e1003212.
61. Smetsers SE, Velleuer E, Dietrich R, Wu T, Brink A, Buijze M, et al. Noninvasive molecular screening for oral precancer in Fanconi anemia patients. Cancer Prev Res 2015;11:1102-11.
62. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013;9: 974-6.
63. KaneM. Preventing cancer with vaccines: progress in the global control of cancer. Cancer Prev Res 2012;1:24-9.
64. Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prev Res 2012;1:18-23.
65. Herrero R, Gonzalez P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol 2015;5:e206-16.
66. Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica vaccine trial. Cancer Prev Res 2013;11:1242-50.
67. Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol 2015, doi.org/10.1016/S1470-2045 (15)00414-3.
68. Kenter GG1, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;19:1838-47.
69. Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double blind, placebo-controlled phase 2b trial. Lancet. 2015 Sep 16 [Epub ahead of print].
70. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol 2015;29:3235-42.
71. Fakhry C, Rosenthal BT, Clark DP,GillisonML. Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal "pap-test equivalent" in high-risk populations. Cancer Prev Res 2011;9: 1378-84.
72. Fahkry C, Andersen KK, Christensen J, Agrawal N, Eisele DW. The impact of tonsillectomy upon the risk of oropharyngeal carcinoma diagnosis and prognosis in the Danish cancer registry. Cancer Prev Res 2015;7:583-9.
73. Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam MM, Goloubeva O, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res 2009;2:776-81.
74. Zandberg DP, Liu S, Goloubeva OG, Schumaker LM, Cullen KJ. Emergence of HPV16-positive oropharyngeal cancer in Black patients over time: University of Maryland 1992-2007. Cancer Prev Res 2015;1:12-9.
75. Pierce Campbell CM, Kreimer AR, Lin HY, Fulp W, O'KeefeMT, Ingles DJ, et al. Long-term persistence of oral human papillomavirus type 16: the HPV Infection in Men (HIM) study. Cancer Prev Res 2015;3:190-6.
76. Nasti TH, Rudemiller KJ, Cochran JB, Kim HK, Tsuruta Y, Fineberg NS, et al. Immunoprevention of chemical carcinogenesis through early recognition of oncogene mutations. J Immunol 2015;6:2683-95.
77. Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, et al. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology 2014;7:1784-94.
78. Ebben JD, Lubet RA, Gad E, Disis ML, You M. Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: an in vivo study in a murine model of EGFR mutant lung cancer. Mol Carcinog 2015 Sep 7. doi: 10.1002/mc.22405. [Epub ahead of print].
79. Cancer Research UK. Challenge 1: prevention vaccines; 2015 [cited 2015 Dec 2] Available from: https://www.cancerresearchuk.org/funding-forresearchers/how-we-deliver-research/grand-challenge-award/challenge1? wssl=1
80. Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res 2013;1: 18-25.
81. Zelenay S, van der Veen AG, Bottcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 2015;162:1257-70.
82. Yue W, Yang CS, DiPaola RS, Tan XL. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res 2014;7:388-97.
83. Disis ML, Gad E, Herendeen DR, Lai VP, Park KH, Cecil DL, et al. A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. Cancer Prev Res 2013;12:1273-82.
84. Broussard EK, Kim R, Wiley JC, Marquez JP, Annis JE, Pritchard D, et al. Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive tomalignant lesions. Cancer Prev Res 2013;7:666-74.
85. Marzbani E, Inatsuka C, Lu H, Disis ML. The invisible armof immunity in common cancer chemoprevention agents. Cancer Prev Res 2013;8: 764-73.
86. Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr, et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med 2012;134: 134ra62.
87. von Knebel Doeberitz M, KloorM. Towards a vaccine to prevent cancer in Lynch syndrome patients. Familial Cancer 2013;2:307-12.
88. Colditz GA, Wolin KY, Gehlert S. Applying what we know to accelerate cancer prevention. Sci Transl Med 2012;127:127rv4.
89. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin 2015; Oct 29. doi: 10.3322/caac.21320. [Epub ahead of print].
90. Neta G, Sanchez MA, Chambers DA, Phillips SM, Leyva B, Cynkin L, et al. Implementation science in cancer prevention and control: a decade of grant funding by the National Cancer Institute and future directions. Implement Sci 2015;10:4.
91. Vogel VG, Costantino JP, Wickerham DL, CroninWM,Cecchini RS, Atkins JN, et al. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res 2010;6:696-706.
92. Hartmann LC, Degnim AC, Dupont WD. Atypical hyperplasia of the breast. N Engl J Med 2015;13:1271-2.
93. Moss JL, Reiter PL, Brewer NT. Correlates of human papillomavirus vaccine coverage: a state-level analysis. Sex Transm Dis 2015;42:71-75.
94. Sivaram S, Sanchez MA, Rimer BK, Samet JM, Glasgow RE. Implementation science in cancer prevention and control: a framework for research and programs in low-and middle-income countries. Cancer Epidemiol Biomarkers Prev 2014;11:2273-84.
95. Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res 2011;6:793-802.
96. Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, et al. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. Cancer Immunol Res 2015; 11:1257-68.
97. Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, et al. Targeting YAPDependent MDSC Infiltration Impairs Tumor Progression. Cancer Discov 2016;1:1-16.
98. Chu NJ, Armstrong TD, Jaffee EM. Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention. Clin Cancer Res 2015;7:1549-57.
99. Corriden R, Hollands A, Olson J, Derieux J, Lopez J, Chang JT, et al. Tamoxifen augments the innate immune function of neutrophils through modulation of intracellular ceramide. Nat Commun 2015; 6:8369.
100. Lévy J, Cacheux W, Bara MA, L'Hermitte A, Lepage P, Fraudeau M, et al. Intestinal inhibition of Atg7 prevents tumour initiation through amicrobiome-influenced immune response and suppresses tumour growth. Nat Cell Biol 2015;8:1062-73.
101. Garrett WS. Cancer and the microbiota. Science 2015;6230:80-6.